Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Falster

Showing results (71-80 of 75) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 75 results.
Pharmacoepidemiology and Drug Safety|August 15, 2024
The Medicines Intelligence Data Platform: A Population-Based Data Resource From New South Wales, AustraliaHelga Zoega, Michael O Falster, Malcolm B Gillies, et al.
Diabetes, Obesity & Metabolism|July 16, 2025
Prevalence of SGLT2 inhibitor and GLP1 receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care datasetHannah Wallace, James Wick, Brendon L Neuen, et al.
International Journal of Cancer|January 24, 2012
Self-reported history of infections and the risk of non-Hodgkin lymphoma: an InterLymph pooled analysisNikolaus Becker, Michael O Falster, Claire M Vajdic, et al.
Cancer Research|August 6, 2009
Atopic disease and risk of non-Hodgkin lymphoma: an InterLymph pooled analysisClaire M Vajdic, Michael O Falster, Silvia de Sanjose, et al.
American Journal of Epidemiology|August 20, 2010
Birth order and risk of non-hodgkin lymphoma--true association or bias?Andrew E Grulich, Claire M Vajdic, Michael O Falster, et al.
Pageof 8

Showing results (71-80 of 75) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 75 results.
Pharmacoepidemiology and Drug Safety|August 15, 2024
The Medicines Intelligence Data Platform: A Population-Based Data Resource From New South Wales, AustraliaHelga Zoega, Michael O Falster, Malcolm B Gillies, et al.
Diabetes, Obesity & Metabolism|July 16, 2025
Prevalence of SGLT2 inhibitor and GLP1 receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care datasetHannah Wallace, James Wick, Brendon L Neuen, et al.
International Journal of Cancer|January 24, 2012
Self-reported history of infections and the risk of non-Hodgkin lymphoma: an InterLymph pooled analysisNikolaus Becker, Michael O Falster, Claire M Vajdic, et al.
Cancer Research|August 6, 2009
Atopic disease and risk of non-Hodgkin lymphoma: an InterLymph pooled analysisClaire M Vajdic, Michael O Falster, Silvia de Sanjose, et al.
American Journal of Epidemiology|August 20, 2010
Birth order and risk of non-hodgkin lymphoma--true association or bias?Andrew E Grulich, Claire M Vajdic, Michael O Falster, et al.
Pageof 8